← Back to Search

Alkylating agents

laboratory biomarker analysis for Lymphoma

Phase 2
Waitlist Available
Led By Daniel O. Persky, MD
Research Sponsored by SWOG Cancer Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients may have either measurable or evaluable limited-stage DLBCL
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial will compare PET-directed chemotherapy to standard chemotherapy in treating patients with limited-stage diffuse large B-cell lymphoma.

Eligible Conditions
  • Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Patients with a specific type of lymphoma called limited-stage DLBCL, which can be measured or evaluated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
Secondary outcome measures
Association of Germinal Center B-cell Subtype (GCB) vs Stromal-1 vs Stromal-2 Gene Expression Signatures With PFS or Overall Survival
Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
Overall Survival of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: PET Positive: IFRT +ZevalinExperimental Treatment5 Interventions
Standard IFRT+ Zevalin IV per ABW
Group II: PET Negative: R-CHOPActive Control7 Interventions
R-CHOP x 3 Cycles
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved
fludeoxyglucose F 18
2005
Completed Phase 3
~3970
selective external radiation therapy
2011
Completed Phase 2
~160
yttrium Y 90 ibritumomab tiuxetan
2012
Completed Phase 2
~750

Find a Location

Who is running the clinical trial?

SWOG Cancer Research NetworkLead Sponsor
394 Previous Clinical Trials
265,451 Total Patients Enrolled
37 Trials studying Lymphoma
6,901 Patients Enrolled for Lymphoma
Southwest Oncology GroupLead Sponsor
388 Previous Clinical Trials
262,092 Total Patients Enrolled
36 Trials studying Lymphoma
6,674 Patients Enrolled for Lymphoma
National Cancer Institute (NCI)NIH
13,603 Previous Clinical Trials
40,913,116 Total Patients Enrolled
1,376 Trials studying Lymphoma
381,425 Patients Enrolled for Lymphoma

Media Library

Cyclophosphamide (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT01359592 — Phase 2
Lymphoma Research Study Groups: PET Negative: R-CHOP, PET Positive: IFRT +Zevalin
Lymphoma Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT01359592 — Phase 2
Cyclophosphamide (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01359592 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What objectives does laboratory biomarker analysis typically serve?

"Laboratory biomarker analysis is a helpful tool for treating various illnesses, including lung cancer, small cell lung cancer (SCLC), thyroiditis, and polyangium."

Answered by AI

Is there still availability for prospective participants in this experiment?

"At present, this medical trial is not accepting participants. It was initially posted on September 1st 2011 and last updated on July 6th 2022. However, there are a multitude of other trials currently recruiting - 1749 involving lymphoma patients and 1427 focused on laboratory biomarker analysis."

Answered by AI

Are there any American healthcare facilities conducting this research investigation?

"At the Island Hospital Cancer Care Center in Anacortes, Washington, Gibbs Regional Cancer Center at Spartanburg Regional Medical Centre and the Cancer Center of Kansas - Wellington are all sites offering this trial. In addition to these locations there are a further 100 clinics participating."

Answered by AI

What earlier experiments have been done to investigate laboratory biomarker metrics?

"Currently, there are 1427 clinical trials that focus on laboratory biomarker analysis with 311 of those in Phase 3. Whilst the majority is based out of Bethesda, Maryland, over 51726 locations across the world are running studies associated to this treatment."

Answered by AI

What is the scope of participants in this experiment?

"Unfortunately, this trial is not presently accepting candidates. The initial posting was made on September 1st 2011 and the last update occurred July 6th 2022. On a positive note, there are currently 1749 clinical trials searching for lymphoma patients and 1427 laboratory biomarker studies actively seeking participants to join their research efforts."

Answered by AI

Are the results from laboratory biomarker analysis officially validated by the FDA?

"Our team at Power gave laboratory biomarker analysis a score of 2 on the 1 to 3 scale, as there is ample data proving its safety but no existing evidence that it works effectively."

Answered by AI
~12 spots leftby Mar 2025